Abstract
Successful pregnancy outcomes are possible after all types of solid organ transplantation and thousands of successful pregnancies in such women have been reported. As immunosuppressive medications are required to maintain adequate graft and maternal survival, major concerns are the effect of these agents on the fetus and the effect of pregnancy on the well being of mother and graft, against a background of continuing advances and modifications in immunosuppressive therapy.
Women should avoid unnecessary medications during pregnancy but clinicians worry most about teratogens; agents (environmental, pharmaceuticals or other chemicals) that cause abnormal development, whether this be an overt structural birth defect or more subtle derangements of embryonic or fetal development. A concern is that any agent or combination of agents and maternal condition(s) may be teratogenic, a risk that is increased in the transplant population. The goal of immunosuppression is to ensure graft and patient survival by preventing acute rejection. Combinations of agents allow for synergistic effects while minimising drug toxicities. No specific combination has been deemed optimal and the effects of more recently available combinations require further study.
Although there are known theoretical risks to mother and fetus, successful pregnancies are now the rule in transplant recipients. This is without an apparent increase in the type or incidence of malformations in the newborns, and usually with no evidence of graft dysfunction and/or irreversible deterioration either related to prepregnancy graft problems or unpredictable gestational factors.
For immunosuppression, what is best for the mother and her survival should ensure the best outcome for the fetus and, although no specific malformation pattern has been reported to date, there are some interesting trends worthy of continued analyses. A balance of good maternal and graft outcome with the lowest risk of fetal toxicity must be the goal of management.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Murray JE, Reid DE, Harrison JH, et al. Successful pregnancies after human renal transplantation. N Engl J Med 1963; 269: 341–3
Davison JM, Lind T, Uldall PR. Planned pregnancy in a renal transplant recipient. Br J Obstet Gynaecol 1976; 83: 518–27
The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61: 722–9
Vasquez EM. Sirolimus: a new agent for the prevention of renal allograft rejection. Am J Health Syst Pharm 2000; 57(5): 437–51
Morales JM, Andres A, Rengel M, et al. Influence of cyclo-sporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 Suppl. 1: 121–4
Davison JM, Redman CWG. Pregnancy post-transplant: the establishment of a UK registry. BrJ Obstet Gynaecol 1997;104: 1106–7
Finnell RH. Teratology: general considerations and principles. J Allergy Clin Immunol 1999; 103: S337–42
Wilson JG. Current status of teratology: general principles and mechanisms derived from animal studies. In: Handbook of Teratology. New York, NY: Plenum Press, 1977; 1: 47
Armenti VT, Moritz MJ, Davison JM. Drug safety issues in pregnancy following transplantation and immunosuppression. Drug Saf 1998; 19(3): 219–32
Fraser FC, Sajoo A. Teratogenic potential of corticosteroids in humans. Teratology 1995; 51: 45–6
Fraser FC, Fainstat TD. The production of congenital defects in the offspring of pregnant mice treated with cortisone: a progress report. Pediatrics 1951; 8: 527–33
Hou S. Pregnancy in transplant recipients. Med Clin North Am 1989; 73: 667–83
Friedman JM, Polifka JE. The effects of drugs on the fetus and nursing infant: a handbook for health care professionals. Baltimore (MD): John Hopkins University Press, 1996
Yeast JD. Immunosuppressives in pregnant transplant patients-what risks? Pharmacology 1987; 30: 117–24
Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from mother to the fetus. Am J Obstet Gynecol 1973; 115: 1100–6
Registration Committee of the European Dialysis and Transplant Association. Successful pregnancies in women treated by dialysis and kidney transplantation. Br J Obstet Gynaecol 1980; 87: 839–45
Penn I, Makowski EL, Harris P. Parenthood following renal and hepatic transplantation. Transplantation 1980; 30: 397–400
Rudolph J, Schweizer RT, Bartus SA. Pregnancy in renal transplant patients. Transplantation 1979; 27: 26–9
Davison JM. Dialysis, transplantation, and pregnancy. Am J Kidney Dis 1991; 17: 127–32
Leb DE, Weisskopf B, Kanovitz BS. Chromosome aberrations in the child of a kidney transplant recipient. Arch Intern Med 1971; 128: 441–4
Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002; 73(6): 953–9
Johnson M, Flye MW. Long-term follow-up of the renal transplant recipient. In: Flye MW, editor. Principles of organ transplantation. Philadelphia (PA): W.B. Saunders Co., 1989: Chapter 16, 309–10
Washer GF, Schroter GPJ, Starzl TE, et al. Causes of death after kidney transplant. JAMA 1983; 250: 49–54
Tilney NL, Strom TB, Vineyard GC, et al. Factors contributing to the declining mortality rate in renal transplantation. N Eng J Med 1978; 299: 1321–5
Mason RJ, Thomson AW, Whiting PH, et al. Cyclosporine-induced feto-toxicity in the rat. Transplantation 1985; 39: 9–12
Fein A, Vechoropoulos M, Nebel L. Cyclosporin-induced embryotoxicity in mice. Biol Neonate 1989; 56: 165–73
Pickrell MD, Sawers R, Michael J. Pregnancy after renal transplantation: severe intra-uterine growth retardation during treatment with cyclosporin A. BM J 1988; 296: 825
Kovarik JM, Mueller EA, Richard F, et al. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 1996; 62: 759–63
Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599–606
Newstead CG. Tacrolimus in renal transplantation. Nephrol Dial Transplant 1997; 12: 1312–5
Farley DE, Shelby J, Alexander D, et al. The effect of two new immunosuppressive agents FK506 and Didemnin B, in murine pregnancy. Transplantation 1991; 52: 106–10
Jain A, Venkataramanan R, Fung JJ, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997; 64: 559–65
Pirsch JD, Miller J, Deierhoi MH, et al. for the FK506 Kidney Transplant Study Group: a comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977–83
Sollinger HW, Cho S, Danovitch G. Mycophenolate mofetil for the prevention of acute rejection in primary cadaver renal allograft recipients. Transplantation 1995; 60: 225–32
Roche Laboratories. Mycophenolate mofetil and daclizumab package inserts. Nutley, NJ: Roche Laboratories
Wyeth-Ayerst Pharmaceuticals. Sirolimus package insert. Philadelphia, PA: Wyeth Laboratories
Novartis Pharmaceuticals. Basiliximab package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation
Silver RM, Branch DW. The immunology of pregnancy. In: Creasy RK and Resnik R, editors. Maternal-fetal medicine, 4th ed. Philadephia (PA): WB Saunders Company, 1999: 72–89
Yaffe SJ. Introduction. In: Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation, 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 1998: xiii–xix
Davison JM. Pregnancy in renal allograft recipients: problems, prognosis and practicalities. In: Lindheimer MD, Davison JM, editors. Balliere’s Clin Obstet Gynaecol. 8. London (UK): Bailliere Tindall, 1994: 501–27
Armenti VT, Ahlswede KM, Ahlswede BA, et al. National Transplantation Pregnancy Registry -Outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1994; 57: 502–6
Oz BB, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71(8): 1051–5
Kainz A, Harabacz I, Cowlrick IS, et al. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transplant Int 2000; 13(1): S299–300
Armenti VT, Radomski JS, Moritz MJ, et al. National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. In: Cecka JM, Terasaki PI, editors. Clinical Transplants 2001, 7. Los Angeles (CA), UCLA Immunogenetics Center 2002: 97–105
Armenti VT, Moritz MJ, Radomski JS, et al. Pregnancy and transplantation. Graft 2000; 3(2): 59–63
Toma H, Kazunari T, Tokumoto T, et al. Pregnancy in women receiving renal dialysis or transplantation in Japan: a nation-wide survey. Nephrol Dial Transplant 1999; 14: 1511–6
Branch KR, Wagoner LE, McGrory CH, et al. Risks of subsequent pregnancies on mother and newborn in female heart transplant recipients. J Heart Lung Transplant 1998; 17: 698–702
Barrou BM, Gruessner AC, Sutherland DER, et al. Pregnancy after pancreas transplantation in the cyclosporine era. Transplantation 1998; 65: 524–7
Armenti VT, Wilson GA, Radomski JS, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. In: Cecka JM, Terasaki PI, editors. Clinical Transplants 1999, 15. Los Angeles (CA): UCLA Tissue Typing Laboratory, 2000: 111–9
Wegmann TG, Lin H, Guilbert L, et al. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14: 353–6
Da Silva JA, Spector TD. The role of pregnancy in the course and aetiology of rheumatoid arthritis. Clin Rheumatol 1992; 11: 189–94
Funakoshi N, Ohno T, Kanoh T, et al. Agammaglobulinemia in a pregnant woman. Tohoku J Experiment Med 1986; 149(4): 359–65
Sturgiss SN, Davison JM. Effect of pregnancy on long-term function of renal allografts. Am J Kidney Dis 1992; 19: 167–72
First MR, Combs CA, Weiskittel P, et al. Lack of effect of pregnancy on renal allograft survival or function. Transplantation 1995; 59: 472–6
Sturgiss SN, Davison JM. Effect of pregnancy on the long-term function of renal allografts: an update. Am J Kidney Dis 1995; 26: 54–6
Ehrich JHH, Loirat C, Davison JM, et al. Repeated successful pregnancies after kidney transplantation in 102 women (Report by the EDTA Registry). Nephrol Dial Transplant 1996; 11: 1314–7
Salmela KT, Kyllonen LE, Holmberg C, et al. Impaired renal function after pregnancy in renal transplant recipients. Transplantation 1993; 56: 1372–5
Armenti VT, McGrory CH, Cater JS, et al. Pregnancy outcomes in female renal transplant recipients. Transplant Proc 1998; 30: 1732–4
Davison JM. Renal disorders in pregnancy. Curr Opin Obstet Gynecol 2001; 13(2): 109–14
Kozlowska-Boszko B, Lao M, Gaciong Z, et al. Chronic rejection as a risk factor for deterioration of renal allograft function following pregnancy. Transplant Proc 1997; 29: 1522–3
Armenti VT, Herrine SK, Radomski JS, et al. Pregnancy after liver transplantation. Liver Transplant 2000; 6(6): 671–85
Wilson GA, Coscia LA, McGrory CH, et al. National Transplantation Pregnancy Registry: postpregnancy graft loss among female pancreas-kidney recipients. Transplant Proc 2001; 33: 1667–9
Armenti VT, Ahlswede KM, Ahlswede BA, et al. Variables affecting birthweight and graft survival in 197 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1995; 59: 476–9
Vyas S, Kumar A, Piecuch S, et al. Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. Transplantation 1999; 67: 490–2
Pérgola PE, Kancharla A, Riley DJ. Kidney transplantation during the first trimester of pregnancy: Immunosuppression with mycophenolate mofetil, tacrolimus and prednisone. Transplantation 2001; 71(7): 94–7
Di Paolo S, Schena A, Morrone L, et al. Immunologic evaluation during the first year of life of infants born to cyclosporine-treated kidney transplant recipients: analysis of lymphocyte subpopulation and immunoglobulin serum levels. Transplantation 2000; 69(10): 2049–54
Giudice PL, Dubourg L, Hadj-Aïssa A, et al. Renal function of children exposed to cyclosporine in utero. Nephrol Dial Transplant 2000; 15: 1575–9
Willis FR, Findlay CA, Gorrie MJ, et al. Children of renal transplant recipient mothers. J Paediatr Child Health 2000; 36: 230–5
Stanley CW, Gottlieb R, Zager R, et al. Developmental well-being in offspring of women receiving cyclosporine post-renal transplant. Transplant Proc 1999; 31: 241–2
Thiagarajan KD, Easterling T, Davis C, et al. Breast-feeding by a cyclosporine-treated mother. Obstet Gynecol 2001; 97(5): 816–7
Nyberg G, Haljamäe U, Frisenette-Fich C, et al. Breast-feeding during treatment with cyclosporine. Transplantation 1998; 65: 253–5
Scott JR, Branch DW, Holman J. Autoimmune and pregnancy complications in the daughter of a kidney transplant patient. Transplantation 2002; 73(5): 815–6
Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69(5): 834–41
Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil: a prospective randomized study. Transplantation 1999; 68(12): 1865–74
Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38(6): S25–35
Cecka JM. The UNOS Scientific Renal Transplant Registry-ten years of kidney transplants. In: Cecka JM, Terasaki PI, editors. Clinical Transplants 1997, 1. Los Angeles (CA): UCLA Tissue Typing Laboratory, 1998: 1–15
Acknowledgements
The authors acknowledge the staff at transplant centres nationwide who have contributed their time and information to the registry. The authors also acknowledge Stephen R. Dunn, BS and Jacqueline R. Cater, PhD for statistical analyses, and Lisa Coscia, RN, BSN, Robyn Richmond, BS and Andrea Salles for their assistance with the preparation of the manuscript. The NTPR is supported by grants from Novartis Pharmaceuticals Corp., Fujisawa Healthcare, Inc., Roche Laboratories Inc., and Wyeth-Ayerst Pharmaceuticals, Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Armenti, V.T., Moritz, M.J., Cardonick, E.H. et al. Immunosuppression in Pregnancy. Drugs 62, 2361–2375 (2002). https://doi.org/10.2165/00003495-200262160-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200262160-00004